Merck agreed to use Quotient Therapeutics’ somatic genomics platform to identify new drug targets for inflammatory bowel disease, marking Quotient’s latest expansion beyond earlier collaborations. The research deal provides $20 million upfront and sets up potential development, regulatory, and commercial milestones totaling up to about $2.2 billion. Quotient’s platform uses nanorate genome sequencing to study somatic mutations accumulating in disease-relevant cells over a patient’s lifetime. The approach is intended to connect naturally occurring genomic changes in vivo to AI-assisted pathway discovery and druggable target identification. Quotient has previously partnered with Pfizer (cardiovascular and renal) and GSK (respiratory and liver diseases), and also has an IBD-focused platform announcement that aligns with Merck Research Laboratories’ stated immunology priorities. The new pact signals that somatic genomics is increasingly viewed as a way to generate target hypotheses tailored to specific disease biology rather than relying solely on inherited-risk genomics.